| 8.45 0.17 (2.05%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.55 | 1-year : | 12.33 |
| Resists | First : | 9.03 | Second : | 10.55 |
| Pivot price | 6.52 |
|||
| Supports | First : | 6.54 | Second : | 5 |
| MAs | MA(5) : | 8.01 |
MA(20) : | 6.83  |
| MA(100) : | 7.21 |
MA(250) : | 6.12 |
|
| MACD | MACD : | 0 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 82.2 |
D(3) : | 76.9 |
| RSI | RSI(14): 61.6 |
|||
| 52-week | High : | 10.98 | Low : | 3.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KPTI ] has closed below upper band by 10.1%. Bollinger Bands are 74.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.88 - 8.92 | 8.92 - 8.95 |
| Low: | 7.95 - 7.99 | 7.99 - 8.02 |
| Close: | 8.21 - 8.28 | 8.28 - 8.33 |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Mon, 13 Apr 2026
Karyopharm Therapeutics (KPTI) affiliated managers report 1.9%–2.3% stakes - Stock Titan
Mon, 13 Apr 2026
Karyopharm (KPTI) seeks approval for director slate and larger equity plans - Stock Titan
Sat, 11 Apr 2026
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
Fri, 27 Mar 2026
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - Yahoo Finance
Fri, 27 Mar 2026
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - qz.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 49.5 (%) |
| Shares Short | 3,590 (K) |
| Shares Short P.Month | 2,470 (K) |
| EPS | -17.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -16 |
| Profit Margin | -134.3 % |
| Operating Margin | -52.4 % |
| Return on Assets (ttm) | -41.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 11.6 % |
| Gross Profit (p.s.) | 0.64 |
| Sales Per Share | 6.48 |
| EBITDA (p.s.) | -4.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -75 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.47 |
| PEG Ratio | 0 |
| Price to Book value | -0.53 |
| Price to Sales | 1.29 |
| Price to Cash Flow | -2.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|